THE SHORT ANSWER
Does Medicare Cover GLP-1 Weight-Loss Drugs?
By law, basic Medicare Part D coverage excludes drugs used for weight loss (some enhanced plans could offer them as supplemental benefits). Since July 1, 2026, people with eligible Part D coverage who meet CMS's eligibility criteria can get Wegovy (injection and pill), Foundayo, and the Zepbound KwikPen for weight management at $50 per monthly fill through the temporary Medicare GLP-1 Bridge (through December 31, 2027). The Bridge runs outside the Part D benefit, and your prescriber must get prior authorization. Some GLP-1 uses — type 2 diabetes, moderate-to-severe OSA, cardiovascular risk reduction, and noncirrhotic MASH (F2–F3) — may be covered under Part D instead, subject to the plan's formulary, prior authorization and exceptions process.
(Source: CMS Medicare GLP-1 Bridge hub, June 2026)
THE NEW LANDSCAPE
What Changed in 2026
Since Medicare drug coverage (Part D) began in 2006, federal law has excluded drugs used for weight loss from basic Part D coverage (enhanced plans could offer them as supplemental benefits) — so Part D generally hasn't paid for GLP-1 medications prescribed for weight loss, even though it covers nearly all other prescription drugs. Starting July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a temporary demonstration program that uses Section 402(a)(1)(A) of the Social Security Amendments of 1967 (applied to Part D via §1860D-42(b)) to work around that statutory exclusion. Outside the Part D benefit, people with eligible Part D coverage who meet CMS's criteria and get prior authorization can access approved weight-loss GLP-1s for a flat $50 per monthly fill. The Bridge runs through December 31, 2027; CMS has not announced a successor. The BALANCE Model in Part D — designed as the follow-on program — has been delayed, and CMS has not set a new start date.
(Source: CMS press release, May 2026; KFF — BALANCE Model analysis, May 2026)
DRUG-BY-DRUG
Which GLP-1s Medicare Covers
| Drug | Coverage path | Forms covered | Notes |
|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 Bridge (weight loss) | All: injectable pen + oral tablet | Bridge (with conditions) for weight management; may be covered under Part D to reduce cardiovascular risk (adults with established cardiovascular disease and obesity or overweight) or for noncirrhotic MASH (F2–F3), subject to the plan's formulary and prior authorization |
| Foundayo (orforglipron) | GLP-1 Bridge (weight loss) | Tablet (oral) | FDA-approved April 1, 2026; oral pill with no food/water restrictions (per Lilly); a Bridge drug (with conditions) |
| Zepbound (tirzepatide) | GLP-1 Bridge (weight loss) | KwikPen ONLY | Vials and single-dose pens NOT covered by Bridge; may be covered under Part D for moderate-to-severe OSA, subject to the plan's formulary and prior authorization |
| Ozempic (semaglutide) | Part D (may be covered) | Injectable | Type 2 diabetes; subject to the plan's formulary and prior authorization; not a Bridge drug |
| Mounjaro (tirzepatide) | Part D (may be covered) | Injectable | Type 2 diabetes; subject to the plan's formulary and prior authorization; not a Bridge drug |
| Rybelsus (semaglutide) | Part D (may be covered) | Oral tablet | Type 2 diabetes; subject to the plan's formulary and prior authorization; not a Bridge drug |
(Source: CMS Medicare GLP-1 Bridge — Information for Pharmacies, June 2026)
WHICH SYSTEM COVERS YOU
Two Paths: Bridge vs. Part D
Which Medicare system covers your GLP-1 depends on why you're taking it.
If prescribed for weight loss (obesity/overweight):
- The Bridge may be your path — $50 per monthly fill flat — if you have eligible Part D coverage, meet one of CMS's BMI tiers and none of the exclusions. Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization. After the pharmacy sends the claim, your prescriber completes the Bridge prior authorization; the decision comes within 72 hours of submission, mailed to you and sent to your prescriber (through the ePA portal or by fax); claims go to the Bridge central processor (BIN 028918 / PCN MEDDGLP1BR), not your Part D plan. CMS recommends (but does not require) an E66 diagnosis code and a
SEND TO BRIDGE FOR WEIGHT MANAGEMENTnote on the prescription, and you don't need a Part D denial first. - Full Bridge eligibility criteria, covered drugs, costs, and not-approved guidance →
If prescribed for a covered medical indication:
- Your Part D plan is your path — for type 2 diabetes, moderate-to-severe OSA, cardiovascular risk reduction, and noncirrhotic MASH (F2–F3), a GLP-1 may be covered under Part D, subject to the plan's formulary, prior authorization and exceptions process.
- Cost-sharing varies by plan and counts toward your annual out-of-pocket cap.
Wrong path can mean a denial.
The indication on your prescription must match the coverage track you're pursuing — your prescriber attests to it on the Bridge PA form under penalty of perjury. Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026 (CMS hasn't set the 2027 lookback). Mild sleep apnea is not one of CMS's stated exclusions, but you must meet every other requirement. A GLP-1 prescribed to reduce cardiovascular events goes through Part D, not the Bridge. There is no appeals process for a Bridge denial: No appeals process for a Bridge prior-authorization denial: your prescriber can resubmit with more information (Part D appeal rights for Part D coverage decisions still apply).
START HERE
Find Your Path
References
- CMS Medicare GLP-1 Bridge hub. cms.gov
- CMS Medicare GLP-1 Bridge — Information for Pharmacies (June 2026). cms.gov
- CMS press release — "Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries" (May 2026). cms.gov
- KFF — What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid. kff.org
Written by Sujatha Jamwal, Honest Care · Reviewed for coverage accuracy by the Honest Care team
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.